-
1.发明授权Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma 失效用于治疗成人T细胞白血病/淋巴瘤的方法，药物组合物和试剂盒公开(公告)号：US08784797B2
公开(公告)日：2014-07-22
申请号：US13515322
申请日：2009-12-15
申请人： Hugues De The , Ali Bazarbachi , Olivier Hermine
发明人： Hugues De The , Ali Bazarbachi , Olivier Hermine
CPC分类号： A61K38/212 , A61K31/495 , A61K31/505 , A61K31/513 , A61K31/52 , A61K31/536 , A61K31/551 , A61K31/675 , A61K31/7072 , A61K31/708 , A61K33/36 , A61K38/00 , A61K38/21 , A61K45/06 , A61K2300/00
摘要： The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
摘要翻译： 本发明涉及用于治疗成人T细胞白血病/淋巴瘤的方法，药物组合物和试剂盒。 更具体地，本发明涉及用于治疗成人T细胞白血病/淋巴瘤的干扰素，砷化合物和逆转录酶抑制剂的组合。
-
2.发明申请METHODS, PHARMACEUTICAL COMPOSITIONS AND KITS FOR USE IN THE TREATMENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA 失效方法，用于治疗成人T细胞淋巴细胞/淋巴瘤的药物组合物和用具公开(公告)号：US20130004459A1
公开(公告)日：2013-01-03
申请号：US13515322
申请日：2009-12-15
申请人： Hugues De The , Ali Bazarbachi , Olivier Hermine
发明人： Hugues De The , Ali Bazarbachi , Olivier Hermine
CPC分类号： A61K38/212 , A61K31/495 , A61K31/505 , A61K31/513 , A61K31/52 , A61K31/536 , A61K31/551 , A61K31/675 , A61K31/7072 , A61K31/708 , A61K33/36 , A61K38/00 , A61K38/21 , A61K45/06 , A61K2300/00
摘要： The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
摘要翻译： 本发明涉及用于治疗成人T细胞白血病/淋巴瘤的方法，药物组合物和试剂盒。 更具体地，本发明涉及用于治疗成人T细胞白血病/淋巴瘤的干扰素，砷化合物和逆转录酶抑制剂的组合。
-
公开(公告)号：US07976841B2
公开(公告)日：2011-07-12
申请号：US11579088
申请日：2004-04-30
申请人： Renato Monteiro , Olivier Hermine , Ivan Moura , Yves Lepelletier
发明人： Renato Monteiro , Olivier Hermine , Ivan Moura , Yves Lepelletier
IPC分类号： A61K39/395 , C07H21/00 , C07K16/18
CPC分类号： C07K16/2881 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The invention relates to the monoclonal antibody A24 directed against the transferrin receptor. This antibody is in particular useful as an antiproliferative agent.
摘要翻译： 本发明涉及针对转铁蛋白受体的单克隆抗体A24。 该抗体特别可用作抗增殖剂。
-
公开(公告)号：US07727731B2
公开(公告)日：2010-06-01
申请号：US10482037
申请日：2002-06-28
申请人： Alain Moussy , Patrice Dubreuil , Olivier Hermine
发明人： Alain Moussy , Patrice Dubreuil , Olivier Hermine
IPC分类号： C12Q1/02 , C12Q1/18 , C12Q1/48 , G01N33/566
CPC分类号： A61K45/06 , A61K31/00 , A61K31/015 , A61K31/095 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4709 , A61K31/498 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/519 , G01N33/5047 , G01N33/6863 , G01N2333/5403 , G01N2333/70596 , G01N2333/715 , G01N2500/10 , A61K2300/00
摘要： The present invention relates to a screening method allowing the identification and selection of compounds targeting the transphosphorylase (also called phosphotransferase) domain of c-kit, more particularly compounds selected to be potent inhibitors of constitutively activated c-kit, while being unable to inhibit other activation pathways as for example the pathways leading to death of IL-3 dependent cells cultured in presence of IL-3.
摘要翻译： 本发明涉及一种筛选方法，其允许鉴定和选择靶向c-kit的转磷酸化酶（也称为磷酸转移酶）结构域的化合物，更特别的是选择为组成型激活的c-kit的有效抑制剂的化合物，同时不能抑制其它 激活途径，例如导致在IL-3存在下培养的IL-3依赖性细胞死亡的途径。
-
公开(公告)号：US20120135002A1
公开(公告)日：2012-05-31
申请号：US13383847
申请日：2009-07-16
IPC分类号： A61K39/395 , A61K31/4196 , A61K31/4412 , A61K31/44 , A61K31/225 , A61P35/00 , A61P35/02 , A61K31/593 , A61K31/381 , A61K31/59 , A61K31/444
CPC分类号： A61K45/06 , A61K31/4196 , A61K31/4402 , A61K31/593 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising: a) at least one iron uptake inhibitor, and b) at least one vitamin D and/or at least one analog thereof and/or at least one vitamin D receptor modulator, and optionally a pharmaceutically acceptable carrier.
摘要翻译： 本发明涉及药物组合物，其包含：a）至少一种铁吸收抑制剂，和b）至少一种维生素D和/或其至少一种类似物和/或至少一种维生素D受体调节剂，以及任选的药物 可接受的载体
-
公开(公告)号：US20060166281A1
公开(公告)日：2006-07-27
申请号：US10482037
申请日：2002-06-28
申请人： Alain Moussy , Patrice Dubreuil , Olivier Hermine
发明人： Alain Moussy , Patrice Dubreuil , Olivier Hermine
IPC分类号： G01N33/567 , G01N33/53
CPC分类号： A61K45/06 , A61K31/00 , A61K31/015 , A61K31/095 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4709 , A61K31/498 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/519 , G01N33/5047 , G01N33/6863 , G01N2333/5403 , G01N2333/70596 , G01N2333/715 , G01N2500/10 , A61K2300/00
摘要： The present invention relates to a screening method allowing the identification and selection of compounds targeting the transphosphorylase (also called phosphotransferase) domain of c-kit, more particularly compounds selected to be potent inhibitors of constitutively activated c-kit, while being unable to inhibit other activation pathways as for example the pathways leading to death of IL-3 dependent cells cultured in presence of IL-3.
摘要翻译： 本发明涉及一种筛选方法，其允许鉴定和选择靶向c-kit的转磷酸化酶（也称为磷酸转移酶）结构域的化合物，更特别的是选择为组成型激活的c-kit的有效抑制剂的化合物，同时不能抑制其它 激活途径，例如导致在IL-3存在下培养的IL-3依赖性细胞死亡的途径。
-
公开(公告)号：US20130190251A1
公开(公告)日：2013-07-25
申请号：US13635448
申请日：2011-03-18
申请人： Veronique Witko-Sarsat , Didier Bouscary , Magali Pederzoli-Ribeil , Olivier Hermine , Isabelle Dusanter-Fourt
发明人： Veronique Witko-Sarsat , Didier Bouscary , Magali Pederzoli-Ribeil , Olivier Hermine , Isabelle Dusanter-Fourt
IPC分类号： G01N33/68 , A61K31/704 , A61K31/506 , A61K31/713 , A61K38/10
CPC分类号： G01N33/6893 , A61K31/506 , A61K31/704 , A61K31/713 , A61K38/10 , G01N33/57426 , G01N2333/4739 , G01N2800/52
摘要： The present invention concerns a method for predicting the responsiveness of an individual suffering from leukemia to a chemotherapeutic drug. In particular, this method comprises determining the proportion of leukemic cells expressing cytoplasmic PCNA in a biological sample of the individual. The present invention also relates to a tyrosine kinase inhibitor for use for the treatment of an individual suffering from leukemia and having a proportion of leukemic cells expressing cytoplasmic PCNA in a biological sample lower than a predetermined threshold. The invention also pertains to a method for diagnosing whether an individual suffers, or is at risk of suffering, from leukemia.
摘要翻译： 本发明涉及用于预测患有白血病的个体对化疗药物的反应性的方法。 特别地，该方法包括测定个体生物样品中表达细胞质PCNA的白血病细胞的比例。 本发明还涉及用于治疗患有白血病的个体的酪氨酸激酶抑制剂，并且在比预定阈值低的生物样品中具有表达细胞质PCNA的一部分白血病细胞。 本发明还涉及一种用于诊断个体是否患有白血病或患有白血病的风险的方法。
-
公开(公告)号：US20080193453A1
公开(公告)日：2008-08-14
申请号：US11579088
申请日：2004-04-30
申请人： Renato Monteiro , Olivier Hermine , Ivan Moura , Yves Lepelletier
发明人： Renato Monteiro , Olivier Hermine , Ivan Moura , Yves Lepelletier
IPC分类号： A61K39/395 , C07K16/18 , A61P43/00 , C07H21/00
CPC分类号： C07K16/2881 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Abstract The invention relates to the monoclonal antibody A24 directed against the transferrin receptor This antibody is in particular useful as an antiproliferative agent.
摘要翻译： 摘要本发明涉及针对转铁蛋白受体的单克隆抗体A24。该抗体特别可用作抗增殖剂。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.012 秒)
